Minerva Neurosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 9
- Market Cap
- $19.3M
- Introduction
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
Clinical Trials
18
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
- Conditions
- Negative Symptoms in Schizophrenia
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Minerva Neurosciences
- Target Recruit Count
- 17
- Registration Number
- NCT06107803
- Locations
- 🇺🇸
Collaborative Neuroscience Research, LLC, Garden Grove, California, United States
🇺🇸CBH Health, LLC, Gaithersburg, Maryland, United States
🇺🇸Hassman Research Institute, Marlton, New Jersey, United States
A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: MIN-117 2.5 mgDrug: PlaceboDrug: MIN-117 5.0 mg
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Minerva Neurosciences
- Target Recruit Count
- 360
- Registration Number
- NCT03446846
- Locations
- 🇺🇸
Woodland International Research Group, LLC, Little Rock, Arkansas, United States
🇺🇸Collaborative Neuroscience Network, LLC, Torrance, California, United States
🇺🇸Pacific Clinical Research Medical Group, Upland, California, United States
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
- Conditions
- Negative Symptoms of Schizophrenia
- Interventions
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Minerva Neurosciences
- Target Recruit Count
- 515
- Registration Number
- NCT03397134
- Locations
- 🇺🇸
Woodland Research Northwest, Rogers, Arkansas, United States
🇺🇸ProScience Research Group, Culver City, California, United States
🇺🇸Collaborative Neuroscience Network, LLC., Torrance, California, United States
A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Minerva Neurosciences
- Target Recruit Count
- 23
- Registration Number
- NCT03072056
- Locations
- 🇮🇪
Biokinetic Europe, Belfast, Ireland
A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Minerva Neurosciences
- Target Recruit Count
- 14
- Registration Number
- NCT03038646
- Locations
- 🇮🇪
Biokinetic Europe, Belfast, Ireland
- Prev
- 1
- 2
- Next
News
Major Depressive Disorder Pipeline Advances with 75+ Companies Developing Novel Therapies
A comprehensive pipeline report reveals over 75 companies are developing innovative treatments for major depressive disorder, with several promising candidates advancing through Phase III trials.